Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy

BACKGROUND: Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not sufficient to restore normal immune response. Other negative regulators of antit...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Mengke, Yi, Ming, Wu, Yuze, Lyu, Lijuan, He, Qing, Yang, Rui, Zeng, Liang, Shi, Jian, Zhang, Jing, Zhou, Pengfei, Zhang, Tingting, Mei, Qi, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423429/
https://www.ncbi.nlm.nih.gov/pubmed/37573354
http://dx.doi.org/10.1186/s13045-023-01487-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423429/
https://www.ncbi.nlm.nih.gov/pubmed/37573354
http://dx.doi.org/10.1186/s13045-023-01487-5

Ejemplares similares